187 related articles for article (PubMed ID: 33241710)
1. Elevated RUNX1 is a prognostic biomarker for human head and neck squamous cell carcinoma.
Feng X; Zheng Z; Wang Y; Song G; Wang L; Zhang Z; Zhao J; Wang Q; Lun L
Exp Biol Med (Maywood); 2021 Mar; 246(5):538-546. PubMed ID: 33241710
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 promotes MAPK signaling to increase tumor progression and metastasis via OPN in head and neck cancer.
Liu K; Hu H; Jiang H; Zhang H; Gong S; Wei D; Yu Z
Carcinogenesis; 2021 Apr; 42(3):414-422. PubMed ID: 33175152
[TBL] [Abstract][Full Text] [Related]
3. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
[TBL] [Abstract][Full Text] [Related]
4. Specificity protein 1/microRNA-92b forms a feedback loop promoting the migration and invasion of head and neck squamous cell carcinoma.
Pang P; Fang H; Wu H; Wang S; Liu M; Jin S; Qi Z; Li Z; Liu F; Sun C
Bioengineered; 2021 Dec; 12(2):11397-11409. PubMed ID: 34905435
[TBL] [Abstract][Full Text] [Related]
5. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
[TBL] [Abstract][Full Text] [Related]
6. Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.
Wang Y; Liu P; Zhang Z; Wang J; Cheng Z; Fan C
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34505628
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA MEG3 decreases the growth of head and neck squamous cell carcinoma by regulating the expression of miR-421 and E-cadherin.
Ji Y; Feng G; Hou Y; Yu Y; Wang R; Yuan H
Cancer Med; 2020 Jun; 9(11):3954-3963. PubMed ID: 32277605
[TBL] [Abstract][Full Text] [Related]
9. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma.
Diao P; Ge H; Song Y; Wu Y; Li J; Li Z; Yang J; Wang Y; Cheng J
J Cell Mol Med; 2019 Jun; 23(6):4269-4280. PubMed ID: 30950191
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
12. CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
Wu Z; Zhu Z; Wu W; Hu S; Cao J; Huang X; Xie Q; Deng C
Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3143-3156. PubMed ID: 38507078
[TBL] [Abstract][Full Text] [Related]
13. Rh type C-glycoprotein functions as a novel tumor suppressor gene by inhibiting tumorigenicity and metastasis in head and neck squamous cell carcinoma.
Xu W; Zou H; Wei Z; Song C; Tang C; Yin X; Wang Y; Han S; Cai Y; Han W
Aging (Albany NY); 2019 Jun; 11(11):3601-3623. PubMed ID: 31170090
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma.
Xiong HG; Li H; Xiao Y; Yang QC; Yang LL; Chen L; Bu LL; Zhang WF; Zhang JL; Sun ZJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):278. PubMed ID: 31238980
[TBL] [Abstract][Full Text] [Related]
15. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.
Li B; Zhu J; Meng L
Mol Med Rep; 2019 Feb; 19(2):877-884. PubMed ID: 30535476
[TBL] [Abstract][Full Text] [Related]
16. KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA.
Lu Y; Wang Y; Zhang L; Ma Z; Yu K; Shu Y; Zou X; Yang J; Liu X; Wang C; Du Y; Li Q
Cancer Lett; 2024 May; 590():216869. PubMed ID: 38593918
[TBL] [Abstract][Full Text] [Related]
17. A Study on the Correlations of the miR-31 Expression with the Pathogenesis and Prognosis of Head and Neck Squamous Cell Carcinoma.
Qiang H; Zhan X; Wang W; Cheng Z; Ma S; Jiang C
Cancer Biother Radiopharm; 2019 Apr; 34(3):189-195. PubMed ID: 30628842
[TBL] [Abstract][Full Text] [Related]
18. Integrin alpha 6 as a stemness driver is a novel promising target for HPV (+) head and neck squamous cell carcinoma.
An JS; Moon JH; Kim C; No JK; Eun YG; Chang Lim Y
Exp Cell Res; 2021 Oct; 407(2):112815. PubMed ID: 34496296
[TBL] [Abstract][Full Text] [Related]
19. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antioxidant network proteins as novel prognostic biomarkers for head and neck cancer patients.
Wicker CA; Takiar V; Suganya R; Arnold SM; Brill YM; Chen L; Horbinski CM; Napier D; Valentino J; Kudrimoti MR; Yu G; Izumi T
Oral Oncol; 2020 Dec; 111():104949. PubMed ID: 32801084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
